Related Experiment Video
Updated: May 13, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Imaging epigenetics in Alzheimer's disease
Simone Lista1, Francesco G Garaci, Nicola Toschi
1Department of Psychiatry, Goethe-University, Frankfurt am Main, Germany. slista@libero.it.
Current Pharmaceutical Design
|February 26, 2013
Summary
Epigenetic mechanisms are crucial in Alzheimer's disease (AD) development. Integrating imaging epigenetics offers new avenues for understanding AD and developing treatments.
Area of Science:
- Neuroscience
- Genetics
- Epigenetics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline.
- Epigenetic mechanisms, which alter gene expression without changing the DNA sequence, are increasingly implicated in AD pathogenesis.
- Current research highlights dysregulation of DNA and histone modifications in AD.
Purpose of the Study:
- To explore the role of epigenetic mechanisms in Alzheimer's disease development and progression.
- To review emerging therapeutic strategies targeting epigenetic pathways.
- To discuss advancements in methods for studying epigenetic alterations and their integration with genetic neuroimaging.
Main Methods:
- Review of current scientific literature on epigenetics and Alzheimer's disease.
- Analysis of high-throughput sequencing approaches for DNA methylation and chromatin analysis.
- Integration of genetic neuroimaging techniques with epigenetic markers.
Main Results:
- Epigenetic modifications, including DNA methylation and histone alterations, are dysregulated in Alzheimer's disease.
- Specific epigenetic pathways are emerging as therapeutic targets.
- Advancements in sequencing and neuroimaging facilitate deeper understanding of AD.
- The integration of genetic and epigenetic data holds significant promise.
Conclusions:
- Epigenetic dysregulation plays a critical role in the pathogenesis of Alzheimer's disease.
- Novel therapeutic strategies targeting epigenetic modifications are under development.
- The emerging field of imaging epigenetics offers a promising approach to unraveling AD complexities and developing biomarkers and treatments.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...